![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, April 08, 2011 12:58:58 PM
19 minutes agoDow Jones
By Katharina Bart
Of DOW JONES NEWSWIRES
ZURICH (Dow Jones)--Novartis AG (NVS) Friday said it will limit its application for cancer drug Afinitor in the U.S. to one type of cancerous tumor only, dealing a potential blow to the Swiss drugmaker's pipeline of new treatments.
The Basel-based firm said it is now asking the U.S. Food and Drug Administration to approve Afinitor only to treat advanced pancreatic neuroendocrine tumors, a rare form of cancer that has recently received broader attention after it became public that Apple Inc. (AAPL) Chief Executive Steve Jobs had the disease.
This means that Novartis is effectively dropping Afinitor to treat advanced neuroendocrine tumors of gastrointestinal and lung origin after feedback from the health regulator.
"Novartis remains committed to patients with advanced neuroendocrine tumors and will continue to conduct studies in patients with advanced carcinoid tumors, where there is a critical unmet need," the company said.
Afinitor is also being studied in late-stage clinical trials for several other cancers, including advanced breast cancer. The drug, which in 2010 more than tripled sales to $243 million, is expected by analysts to become a blockbuster with more than $1 billion in annual sales.
Had Afinitor been able to clinch approval to treat different cancer types it could have--together with multiple-sclerosis pill Gilenya, which could net more than $3 billion in annual peak sales--helped reduce the sales loss impact from the patent expiry of heart drug Diovan.
Diovan, Novartis' best-selling drug, which had annual sales of more than $6 billion in 2010, will start to lose patent protection in some markets this year. Likewise, cancer medicine Femara, which has more than $1 billion in revenue, will face generic competition in 2011, which is likely to result in a steep sales slump. Depending on the number of generic entrants, sales can drop more than 50% after patent rights mature.
Novartis has said that, while it will continue to stick to its strategy of a diversified pharmaceutical company--the firm also owns a large generics, vaccines and eye-care treatment business--the Swiss drugs giant will push for the development of new drugs.
With more than 10% of its sales going into research and development, Novartis wants to boost the ratio of its specialized medicines over the next few years. Currently, Novartis generates around 20% of its drug sales with medicines that have recently been launched.
-By Katharina Bart, Dow Jones Newswires; +41 43 443 8043; katharina.bart@dowjones.com
Recent NVS News
- Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14 • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Lindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitarget • Business Wire • 08/28/2024 04:16:00 PM
- Lindy Biosciences conclut un accord de licence et de collaboration avec Novartis pour l’innovation en matière d’administration de médicaments à cibles multiples • Business Wire • 08/28/2024 04:07:00 PM
- Lindy Biosciences schließt Lizenzierungs- und Kooperationsvereinbarung mit Novartis für Wirkstoffabgabeinnovation für mehrere Zielmoleküle ab • Business Wire • 08/28/2024 04:06:00 PM
- Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation • Business Wire • 08/28/2024 10:58:00 AM
- IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts • IH Market News • 08/26/2024 12:58:21 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/15/2024 08:30:06 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/13/2024 08:31:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 07:30:35 PM
- Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) • PR Newswire (US) • 08/07/2024 11:38:00 PM
- Google Faces Antitrust Ruling; SunPower Files for Bankruptcy and Business Sale – Latest Business News • IH Market News • 08/06/2024 09:44:42 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/02/2024 08:30:48 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 08/01/2024 08:30:53 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/31/2024 08:30:44 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/30/2024 08:30:54 PM
- Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 07/30/2024 11:00:00 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/29/2024 08:30:54 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/25/2024 08:30:58 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/18/2024 08:30:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/18/2024 10:09:04 AM
- TSMC Net Profit Hits $7.6B; Nokia Sees 32% Decline in Operating Profit; Novartis Boosts Outlook After Profit Surge • IH Market News • 07/18/2024 09:53:54 AM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 07/11/2024 08:30:53 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 06/17/2024 08:30:09 PM
- Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio • PR Newswire (US) • 05/25/2024 10:15:00 AM
- Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo • PR Newswire (US) • 05/25/2024 10:00:00 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM